Sarcopenia and risk of nonalcoholic fatty liver disease: A meta-analysis

Wijarnpreecha, Karn; Panjawatanan, Panadeekarn; Thongprayoon, Charat; Jaruvongvanich, Veeravich; Ungprasert, Patompong

doi:10.4103/sjg.sjg_237_17

Cited by 60 publications

(48 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Presence of excess (visceral) fat mass is a well‐established risk factor for NAFLD, independent of BMI . Recently, emerging evidence suggested that low skeletal muscle mass (or presarcopenia) also contributes to the risk of NAFLD . Indeed, because skeletal muscle mass is the primary tissue responsible for insulin‐mediated glucose disposal, skeletal muscle plays an important role in glucose homeostasis and insulin resistance, which are key in the pathogenesis of NAFLD …”

Section: Introductionmentioning

confidence: 99%

“…(6,7) Recently, emerging evidence suggested that low skeletal muscle mass (or presarcopenia) also contributes to the risk of NAFLD. (8)(9)(10) Indeed, because skeletal muscle mass is the primary tissue responsible for insulin-mediated glucose disposal, skeletal muscle plays an important role in glucose homeostasis and insulin resistance, which are key in the pathogenesis of NAFLD. (11) However, evidence on the association between skeletal muscle mass and NAFLD predominantly originates from young Asian populations with a high BMI.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Nonalcoholic Fatty Liver Disease in The Rotterdam Study: About Muscle Mass, Sarcopenia, Fat Mass, and Fat Distribution

Alferink

Trajanoska

Erler

et al. 2019

Journal of Bone and Mineral Research

View full text Add to dashboard Cite

Nonalcoholic fatty liver disease (NAFLD) is the most prevalent liver disease worldwide. Obesity is a major risk factor for NAFLD and recently, low skeletal muscle mass emerged as additional risk factor for NAFLD. However, the different contributions of body mass index (BMI) to the risk of NAFLD are not yet well‐known. We therefore studied body composition and muscle function with NAFLD in an elderly population‐based study. Participants of European descent underwent dual‐energy X‐ray absorptiometry (DXA) and hepatic ultrasonography. NAFLD was defined as liver steatosis in absence of secondary causes for steatosis. Skeletal muscle index (SMI) was defined as appendicular lean mass/height2 and (pre)sarcopenia was defined using the European Working Group on Sarcopenia in Older People (EWGSOP) consensus guidelines. All analyses were stratified by sex and BMI (cut point: 25 kg/m2) and adjusted for age, weight, height, homeostasis model assessment of insulin resistance (HOMA‐IR), triglycerides, and android‐fat‐to‐gynoid‐fat ratio (AGR). We included 4609 participants, of whom 1623 had NAFLD (n = 161 normal‐weight and n = 1462 overweight). Presarcopenia and sarcopenia prevalence was low (5.9% and 4.5%, respectively) and both were not associated with NAFLD. SMI was associated with less NAFLD in normal‐weight women (OR, 0.48; 95% CI, 0.29 to 0.80). A similar association for SMI and NAFLD was seen in normal‐weight men, but significance dissipated after adjustment for AGR (OR, 0.63; 95% CI, 0.39 to 1.02). Generally, fat mass was a better predictor for NAFLD than lean mass. In particular, android fat mass was associated with all NAFLD subgroups (OR from 1.77 in overweight men to 8.34 in normal‐weight women, p max = 0.001), whereas substitution of gynoid fat mass for other body components had a significant protective association with NAFLD in every subgroup, but normal‐weight men. Likewise, AGR was the best performing predictor for NAFLD prevalence (OR from 1.97 in normal‐weight men to 4.81 in normal‐weight women, p max < 0.001). In conclusion, both high fat mass and low SMI were associated with normal‐weight NAFLD. However, fat distribution (as assessed by AGR) could best predict NAFLD prevalence. © 2019 The Authors. Journal of Bone and Mineral Research Published by Wiley Periodicals, Inc.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Nonalcoholic Fatty Liver Disease in The Rotterdam Study: About Muscle Mass, Sarcopenia, Fat Mass, and Fat Distribution

Alferink

Trajanoska

Erler

et al. 2019

Journal of Bone and Mineral Research

View full text Add to dashboard Cite

show abstract

“…fatty liver disease (NAFLD) [9][10][11][12] and nonalcoholic steatohepatitis (NASH) [13][14][15]. In addition, it has been reported that weight-adjusted SMI is associated with insulin sensitivity [16].…”

mentioning

confidence: 99%

Creatinine/(cystatin C × body weight) ratio is associated with skeletal muscle mass index

et al. 2020

View full text Add to dashboard Cite

We have previously reported that the creatinine (Cre) to cystatin C (CysC) ratio is associated with height-adjusted skeletal muscle mass index (SMI). However, weight-adjusted SMI is reported to be a more useful marker of insulin sensitivity than height-adjusted SMI. Thus, we hypothesized that the creatinine to (cystatin C × body weight [BW]) relationship (Cre/ [CysC × BW]) might be associated with weight-adjusted SMI. In this cross-sectional study of 169 males and 132 females, a body composition analyzer was used and the weight-adjusted SMI was calculated as (absolute muscle mass [kg]/BW [kg]) × 100. The cut-off of low muscle mass was defined as weight-adjusted SMI <37.0% for males and <28.0% for females. The Cre/(CysC × BW) was correlated with weight-adjusted SMI in both males (r = 0.484, p < 0.001) and females (r = 0.538, p < 0.001). In addition, Cre/(CysC × BW) was associated with weight-adjusted SMI in both males (standardized β = 0.493, p < 0.001) and females (standardized β = 0.570, p < 0.001) after adjusting for covariates. According to the receiver operator characteristic (ROC) curve analysis, the optimal cut-off point of Cre/(CysC × BW) for low muscle mass was 0.0145 (area under the ROC curve [AUC] 0.756 [95% confidence interval {95% CI} 0.644-0.842], sensitivity = 0.96, specificity = 0.47, p < 0.001) in males and 0.0090 (AUC 0.976 [95% CI 0.894-0.995], sensitivity = 1.00, specificity = 0.93, p < 0.001) in females. There is a correlation between Cre/(CysC × BW) and weight-adjusted SMI. The Cre/(CysC × BW) could be a practical screening marker for low muscle mass.

show abstract

“…In the past, sarcopenia was only regarded as part of aging; more recently, it was recognized as a progressive disease frequently associated with cardiometabolic disorders including diabetes mellitus, metabolic syndrome and cardiovascular disease (6). Interestingly, several studies have reported the presence of sarcopenia in subjects with NAFLD, and sarcopenia is emerging as a novel risk factor for the development of NAFLD (7)(8)(9)(10).…”

mentioning

confidence: 99%

“…Three recent distinct meta-analyses with overlap of selected articles have estimated the risk of NAFLD among patients with sarcopenia. The first meta-analysis, summarizing the data available through November 2016, included five cross-sectional studies (of whom two in the form of abstract) with 27,804 participants (8). Patients with sarcopenia had a 1.5-fold increased risk of NAFLD compared to those without sarcopenia [odds ratio (OR) =1.54; 95% confidence interval (CI), 1.05-2.26].…”

mentioning

confidence: 99%